齐拉西酮与利培酮治疗首发精神分裂症的疗效及不良反应  

Efficacy and Adverse Reactions of Ziprasidone and Risperidone in the Treatment of First-episode Schizophrenia

作　　者：韩霞 HAN Xia(Second People's Hospital of Liaoyuan City,Liaoyuan 136200,China)

机构地区：[1]吉林省辽源市第二人民医院,吉林辽源136200

出　　处：《中国医药指南》2020年第32期72-74,共3页Guide of China Medicine

摘　　要：目的比较首发精神分裂症患者实施治疗过程中应用齐拉西酮与利培酮的临床效果与安全性。方法本次试验研究的对象为首发精神分裂症患者88例,入院时间为2018年2月至2019年3月,根据随机数字表法将患者分为两组,给予齐拉西酮治疗的A组和接受利培酮治疗的B组。对两组患者治疗的疗效与安全性进行分析和比较。结果A组与B组患者治疗效果、治疗前、治疗后2周阳性症状分、阴性症状分、一般病理分和阳性和阴性精神症状评定量表(PANSS)总分比较均无明显差异(P>0.05);A组患者兴奋、失眠、嗜睡、焦虑及肝功能异常、口干、视物模糊、便秘、恶心呕吐及头痛、心动过速等并发症发生率与B组患者均无明显差异(P>0.05);A组患者肌强直、震颤、静坐不能、血压下降及体质量增加等不良反应发生率均明显低于B组患者(P<0.05)。结论首发性精神分裂症患者实施治疗过程中应用齐拉西酮与利培酮的治疗效果相当,治疗一段时间后齐拉西酮在阳性症状分、阴性症状分、一般病理分和PANSS总分等情况上存在一定优势,且其肌强直、震颤、静坐不能、血压下降以及体质量增加等不良反应的发生较少,相对于利培酮来说齐拉西酮更加安全、有效,可以将其作为理想的首发精神分裂症患者治疗药物。Objective To compare the clinical eff ects and safety of ziprasidone and risperidone in the treatment of fi rst-episode schizophrenia patients.Methods The subjects of this trial were 88 patients with fi rst-episode schizophrenia.The admission time was from February 2018 to March 2019.The patients were divided into two groups according to the random number table method.Group A was given ziprasidone treatment.Group B receiving risperidone treatment.The effi cacy and safety of the two groups of patients were analyzed and compared.Results There was no signifi cant diff erence in the treatment eff ect,positive symptom score,negative symptom score,general pathology score,and positive and negative psychiatric symptom rating scale(PANSS)total score of patients in group A and B before treatment and 2 weeks after treatment(P>0.05);The incidence of complications such as excitement,insomnia,drowsiness,anxiety and abnormal liver function,dry mouth,blurred vision,constipation,nausea and vomiting,headache,and tachycardia in group A were not signifi cantly diff erent from those in group B(P>0.05);the incidence of adverse reactions such as myotonia,tremor,akathisia,blood pressure drop,and increase in body mass in group A were significantly lower than those in group B(P<0.05).Conclusion The therapeutic eff ects of ziprasidone and risperidone in the treatment of patients with fi rst-episode schizophrenia are equivalent.After a period of treatment,ziprasidone has positive symptom score,negative symptom score,general pathology score,and PANSS total score.There are certain advantages in the above,and the occurrence of adverse reactions such as muscle rigidity,tremor,akathisia,blood pressure drop,and increase in body mass are less frequent.Compared with risperidone,ziprasidone is safer and more eff ective and can be regarded as an ideal the fi rst treatment drug for patients with schizophrenia.

关 键 词：首发精神分裂症 齐拉西酮 利培酮 阳性和阴性精神症状评定量表 不良反应 

分 类 号：R749.3[医药卫生—神经病学与精神病学]